Craig A. Wheeler - 14 May 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship: Director
Issuer ticker: APLS
Reported as of: 14 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 May 2026, 19:19:47 UTC
Prior SEC filing: 27 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ David Watson, attorney-in-fact for Craig Wheeler

Key filing fact

Craig A. Wheeler filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 14 May 2026.

Key facts

This page summarizes Craig A. Wheeler's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 May 2026, 19:19.

Change

Previous filing in this sequence was filed on 27 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001229450 Primary reporting owner

WHEELER CRAIG A

Relationship: Director
Address: C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM
Signature: /s/ David Watson, attorney-in-fact for Craig Wheeler
Signature date: 14 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APLS transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -24,444
Change %: -100%
Price
Shares after: 0
Date: 14 May 2026
Ownership: Direct
Footnotes: F1, F2, F3

APLS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -15,110
Change %: -100%
Price
Shares after: 0
Date: 14 May 2026
Ownership: Direct
Footnotes: F4, F5

APLS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -7,961
Change %: -100%
Price
Shares after: 0
Date: 14 May 2026
Ownership: Direct
Footnotes: F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APLS transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -28,195
Change %: -100%
Price
Shares after: 0
Date: 14 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,195
Exercise price: $18.20
Footnotes: F6

APLS transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -14,684
Change %: -100%
Price
Shares after: 0
Date: 14 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,684
Exercise price: $25.12
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Craig A. Wheeler is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"),

Footnote F2

(continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,

Footnote F3

(continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.

Footnote F4

Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

Footnote F5

(continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Footnote F6

Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.